RxDoctor Payments Data

Kevin Kissel

Optometrist · Pineville, WVNPI 1770553943

Payments from drug & device makers

$692in general payments, 2019–2025

Across 11 payments — averaging $62.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$229
  • LKC Technologies, Inc.$100
  • AbbVie$93
  • Dompe US, Inc.$75
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$70
  • Aerie Pharmaceuticals, Inc.$68
  • plus $58 from 2 others

What the payments were for

  • Food & beverage$692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$692 in reported general payments places this provider in the 45th percentile of 210 optometrist providers in West Virginia.

See all optometrist providers in West Virginia

Medicare billing

Part B allowed, 2024
$46,816
Medicare patients
247
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$33,164
LumiganBimatoprost24$9,093
Travoprost36$8,347
Loteprednol Etabonate32$3,916
Azelastine Hcl132$3,793
Latanoprost171$1,920
Brimonidine Tartrate27$1,500
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat40$902
Timolol Maleate17$735
Tobramycin-DexamethasoneTobramycin/Dexamethasone22$720
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$428
Prednisolone Acetate12$414
Dorzolamide Hcl28$295
ErythromycinErythromycin Base12$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$93$42,25757 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$70$3,91632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 210 optometrist providers in West Virginia.

Other optometrist in Pineville

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →